Müller-Tidow, Carsten
Carsten Müller-Tidow
VIAF ID: 175284971 ( Personal )
Permalink: http://viaf.org/viaf/175284971
Preferred Forms
- 100 0 _ ‡a Carsten Müller-Tidow
- 100 1 _ ‡a Müller-Tidow, Carsten
4xx's: Alternate Name Forms (13)
5xx's: Related Names (2)
Works
Title | Sources |
---|---|
Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial | |
Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study | |
Expressionsanalyse und funktionelle Charakterisierung von Zyklin A1 und der Interaktionspartner des Zyklin A1-CDK2-Komplexes | |
Funktionelle Bedeutung von snoRNAs bei der Akuten Myeloischen Leukämie | |
Genomic investigation and successful containment of an intermittent common source outbreak of OXA-48-producing enterobacter cloacae related to hospital shower drains | |
Identification of RPS6KA1 as a mediator of resistance to Venetoclax/Azacytidine-combination treatment in Acute Myeloid Leukemia by genome-scale CRISPR/Cas9 knockout screening | |
Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation | |
Inhibitor of Growth Protein 5 (ING5) Depends on INCA1 as a Co-Factor for Its Antiproliferative Effects | |
Integrated RNAi screening identifies the NEDDylation pathway as a synergistic partner of azacytidine in acute myeloid leukemia | |
landscape of small nucleolar RNA expression and potential roles of RNA modifications in multiple myeloma | |
Leukemia stem cell fates are determined by DNA methylation levels | |
A Limited Role for the Cell Cycle Regulator Cyclin A1 in Murine Leukemogenesis | |
Maintenance of Leukemia-Initiating Cells Is Regulated by the CDK Inhibitor Inca1 | |
Mutations of the EPHB6 Receptor Tyrosine Kinase Induce a Pro-Metastatic Phenotype in Non-Small Cell Lung Cancer | |
Myeloische Neoplasien | |
Patients with Acute Myeloid Leukemia Admitted to Intensive Care Units: Outcome Analysis and Risk Prediction | |
PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups | |
A Phase I Dose Escalation Study of the Triple Angiokinase Inhibitor Nintedanib Combined with Low-Dose Cytarabine in Elderly Patients with Acute Myeloid Leukemia | |
Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas | |
pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients | |
Proteinase-Activated Receptor 1 (PAR1) Regulates Leukemic Stem Cell Functions | |
Receptor protein-tyrosine phosphatases controlling activity of the oncoprotein FLT3 ITD | |
Third-generation CD19.CAR-T cell-containing combination therapy in Scl70+ systemic sclerosis |